Analysis of diagnostic and prognostic value of lncRNA MEG3 in cervical cancer

  • Authors:
    • Shuqiong Wan
    • Huanqiu Zhao
  • View Affiliations

  • Published online on: August 31, 2020     https://doi.org/10.3892/ol.2020.12044
  • Article Number: 183
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to explore the diagnostic and prognostic value of lncRNA maternally expressed 3 (MEG3) in cervical cancer. Eighty‑four patients with cervical cancer from February 2013 to March 2014 were enrolled in the observation group (OG), and another 58 female subjects who underwent physical examination at Huangshi Central Hospital were enrolled as the control group (CG). The serum MEG3 expression of patients in the two groups was detected by RT‑qPCR, and the ability of MEG3 to aid in the diagnosis of cervical cancer, lymph node metastasis and FIGO staging, as well as to predict mortality was evaluated by ROC curve. In addition, the patients in the OG were divided into high‑ and low‑expression groups according to the median value of MEG3. Kaplan Meier was employed to analyze the survival status, and Cox regression to analyze the independent prognostic factors of cervical cancer patients. The results of the present study revealed that the serum MEG3 expression in the OG was significantly lower than that of the CG (P<0.05). The area under the curve (AUC) of MEG3 in diagnosing cervical cancer was 0.844, the AUC in predicting mortality was 0.858, while that in diagnosing lymph node transfer was 0.707, and that in diagnosing FIGO staging was 0.791. The 5‑year survival rate of the high‑expression group was higher than that of the low‑expression group (P=0.020). Multivariate analysis indicated that MEG3 (HR, 0.173; 95 CI%, 0.028‑0.919), lymph node metastasis (HR, 2.259; 95 CI%, 1.004‑5.025) and FIGO staging (HR, 0.008; 95 CI%, 1.453‑6.248) were independent prognostic factors for cervical cancer patients. Collectively, lncRNA MEG3 may be a diagnostic marker and prognostic indicator for cervical cancer, and has a certain diagnostic value for lymph node metastasis and FIGO staging. Lymph node metastasis, FIGO stage III and IV, and low MEG3 levels were revealed to be independent prognostic factors for cervical cancer patients.
View Figures
View References

Related Articles

Journal Cover

November-2020
Volume 20 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wan S and Wan S: Analysis of diagnostic and prognostic value of lncRNA MEG3 in cervical cancer. Oncol Lett 20: 183, 2020
APA
Wan, S., & Wan, S. (2020). Analysis of diagnostic and prognostic value of lncRNA MEG3 in cervical cancer. Oncology Letters, 20, 183. https://doi.org/10.3892/ol.2020.12044
MLA
Wan, S., Zhao, H."Analysis of diagnostic and prognostic value of lncRNA MEG3 in cervical cancer". Oncology Letters 20.5 (2020): 183.
Chicago
Wan, S., Zhao, H."Analysis of diagnostic and prognostic value of lncRNA MEG3 in cervical cancer". Oncology Letters 20, no. 5 (2020): 183. https://doi.org/10.3892/ol.2020.12044